MedXCell develops off-the-shelf cellular therapies using genetically unmodified effector cells combined with engineered targeting ligands, addressing the need for effective treatments in oncology and immunology. The company transforms scientific breakthroughs into clinical assets by co-developing projects with academic institutions and managing their operational growth until they reach proof-of-concept.
Funding
$9.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer and autoimmune disease treatments often lack specificity, leading to off-target effects and limited efficacy. Developing targeted therapies that can effectively modulate the immune system and directly target diseased cells remains a significant challenge. Existing approaches may also face scalability and regulatory hurdles.
Solution
MedXCell operates as a biotech venture builder, identifying promising scientific breakthroughs and transforming them into clinical assets. The company co-develops early-stage projects with academic institutions, creating self-standing ventures centered around commercially viable ideas. MedXCell focuses on technologies, techniques, and novel applications in major diseases such as cancer, autoimmune, neurological, and degenerative disorders. Its portfolio includes companies developing therapeutic products based on combining genetically unmodified effector cells and engineered targeting ligands, as well as a new family of functional excipient molecules to enhance the activity of biological drugs.
Target Audience
MedXCell targets investors and pharmaceutical companies seeking early-stage biotech assets with innovative therapeutic approaches in oncology, immunology, and related fields.
Features
- Venture building model to create and scale biotech companies.
- Co-development of early-stage projects with academic institutions.
- Focus on oncology, immunology, neurology, and degenerative disorders.
- Portfolio companies with pre-clinical assets.
- Pin™ Platform enables rapid formulation of antibody-effector cell constructs for identified targets.
- Pin™ Platform facilitates scalable manufacturing through the self-assembly process when ligands and cells are mixed.
- Pin™ Platform allows for efficient development and production of diverse drug products with same core drug substances, thereby enabling a simpler regulatory pathway for multiple unique products.